DK0884051T3 - Cancröse metastaseinhibitorer indeholdende uracilderivater - Google Patents
Cancröse metastaseinhibitorer indeholdende uracilderivaterInfo
- Publication number
- DK0884051T3 DK0884051T3 DK97940448T DK97940448T DK0884051T3 DK 0884051 T3 DK0884051 T3 DK 0884051T3 DK 97940448 T DK97940448 T DK 97940448T DK 97940448 T DK97940448 T DK 97940448T DK 0884051 T3 DK0884051 T3 DK 0884051T3
- Authority
- DK
- Denmark
- Prior art keywords
- unsubstituted
- inhibitors containing
- substituted
- uracil derivatives
- containing uracil
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25130396 | 1996-09-24 | ||
| PCT/JP1997/003355 WO1998013045A1 (fr) | 1996-09-24 | 1997-09-22 | Inhibiteurs de metastases cancereuses contenant des derives d'uracile |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0884051T3 true DK0884051T3 (da) | 2005-01-24 |
Family
ID=17220808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK97940448T DK0884051T3 (da) | 1996-09-24 | 1997-09-22 | Cancröse metastaseinhibitorer indeholdende uracilderivater |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6255314B1 (da) |
| EP (1) | EP0884051B1 (da) |
| JP (1) | JP3088758B2 (da) |
| KR (1) | KR100284413B1 (da) |
| AT (1) | ATE284694T1 (da) |
| AU (1) | AU699728B2 (da) |
| CA (1) | CA2238331C (da) |
| DE (1) | DE69731940T2 (da) |
| DK (1) | DK0884051T3 (da) |
| ES (1) | ES2235249T3 (da) |
| PT (1) | PT884051E (da) |
| WO (1) | WO1998013045A1 (da) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4049477B2 (ja) | 1999-03-23 | 2008-02-20 | 大鵬薬品工業株式会社 | 副作用軽減剤 |
| FR2796945B1 (fr) * | 1999-07-30 | 2002-06-28 | Sod Conseils Rech Applic | Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments |
| NZ523970A (en) * | 2003-02-04 | 2005-02-25 | Ind Res Ltd | Process for preparing inhibitors of nucleoside phoshorylases and nucleosidases |
| US8415315B2 (en) | 2004-05-06 | 2013-04-09 | University Of Central Florida Research Foundation, Inc. | Methods and compositions for inhibiting the proliferation of cancer cells |
| SI1849470T2 (sl) * | 2005-01-26 | 2024-05-31 | Taiho Pharmaceutical Co., Ltd. | Zdravilo proti raku, ki vsebuje alfa,alfa,alfa-trifluorotimidin in zaviralec timidin-fosforilaze |
| US7799783B2 (en) | 2005-01-26 | 2010-09-21 | Taiho Pharmaceutical Co., Ltd. | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
| CA2649256C (en) | 2006-04-13 | 2013-09-10 | Taiho Pharmaceutical Co., Ltd. | Therapeutic agent for inflammatory bowel disease |
| RU2435587C2 (ru) * | 2006-06-30 | 2011-12-10 | Тайхо Фармасьютикал Ко., Лтд. | Средство, потенцирующее радиационную терапию |
| TWI429439B (zh) | 2007-10-11 | 2014-03-11 | Taiho Pharmaceutical Co Ltd | And a therapeutic agent for inflammatory bowel disease using a uracil derivative as an active ingredient |
| TWI435725B (zh) * | 2007-10-11 | 2014-05-01 | Taiho Pharmaceutical Co Ltd | The use of a uracil compound for a prophylactic or therapeutic composition for the preparation of cystitis and hepatitis |
| JP2010202591A (ja) * | 2009-03-04 | 2010-09-16 | Hokkaido Univ | 増殖性疾患の内用放射線治療剤 |
| NZ714014A (en) | 2013-05-17 | 2017-06-30 | Taiho Pharmaceutical Co Ltd | Therapeutic effect prediction method for colorectal cancer patient in whom expression of tk1 protein has increased |
| MA38668B2 (fr) | 2013-06-17 | 2019-09-30 | Taiho Pharmaceutical Co Ltd | Cristal stabilisé de chlorhydrate de tipiracil, et son procédé de cristallisation |
| CN105906573A (zh) * | 2015-12-23 | 2016-08-31 | 嘉实（湖南）医药科技有限公司 | 一种替吡嘧啶中间体的制备方法 |
| TWI767945B (zh) * | 2016-10-14 | 2022-06-21 | 義大利商Ｔｅｓ製藥（股份）責任有限公司 | α-胺基-β-羧基己二烯二酸半醛去羧酶之抑制劑 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3450399B2 (ja) * | 1993-12-28 | 2003-09-22 | 大鵬薬品工業株式会社 | 血管新生阻害剤 |
| DE69629156T2 (de) * | 1995-03-29 | 2004-05-06 | Taiho Pharmaceutical Co. Ltd. | Uracilderivate und diese enthaltende antitumoreffekt-verstärker sowie antitumormittel |
-
1997
- 1997-09-22 DE DE69731940T patent/DE69731940T2/de not_active Expired - Lifetime
- 1997-09-22 ES ES97940448T patent/ES2235249T3/es not_active Expired - Lifetime
- 1997-09-22 KR KR1019980703452A patent/KR100284413B1/ko not_active IP Right Cessation
- 1997-09-22 JP JP10503999A patent/JP3088758B2/ja not_active Expired - Fee Related
- 1997-09-22 PT PT97940448T patent/PT884051E/pt unknown
- 1997-09-22 WO PCT/JP1997/003355 patent/WO1998013045A1/ja active IP Right Grant
- 1997-09-22 EP EP97940448A patent/EP0884051B1/en not_active Expired - Lifetime
- 1997-09-22 CA CA002238331A patent/CA2238331C/en not_active Expired - Fee Related
- 1997-09-22 AT AT97940448T patent/ATE284694T1/de active
- 1997-09-22 US US09/077,209 patent/US6255314B1/en not_active Expired - Lifetime
- 1997-09-22 DK DK97940448T patent/DK0884051T3/da active
- 1997-09-22 AU AU42225/97A patent/AU699728B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| PT884051E (pt) | 2005-03-31 |
| KR100284413B1 (ko) | 2001-03-02 |
| DE69731940D1 (de) | 2005-01-20 |
| ATE284694T1 (de) | 2005-01-15 |
| DE69731940T2 (de) | 2005-05-25 |
| US6255314B1 (en) | 2001-07-03 |
| ES2235249T3 (es) | 2005-07-01 |
| EP0884051A1 (en) | 1998-12-16 |
| AU699728B2 (en) | 1998-12-10 |
| CA2238331C (en) | 2003-02-25 |
| EP0884051B1 (en) | 2004-12-15 |
| WO1998013045A1 (fr) | 1998-04-02 |
| AU4222597A (en) | 1998-04-17 |
| EP0884051A4 (en) | 2001-06-13 |
| CA2238331A1 (en) | 1998-04-02 |
| KR19990067441A (ko) | 1999-08-16 |
| JP3088758B2 (ja) | 2000-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69731940D1 (de) | Uracilderivate enthaltende krebsmetastasen inhibitoren | |
| MX9203551A (es) | Derivados de fenil amidinas utiles como inhibidores de agregacion de plaquetas. | |
| MXPA02011974A (es) | Derivados de quinazolina sustituidos y su uso como inhibidores. | |
| ES2182852T3 (es) | Derivados de prolinamida. | |
| CY1107001T1 (el) | Αζωτουχα ετεροκυκλικα παραγωγα καρβοξαμιδιου ή αλας αυτων ως αντιϊκοι παραγοντες | |
| ATE345122T1 (de) | Stabile emulsionszubereitungen | |
| MY133473A (en) | Haterocyclic glycyl beta-alanine derivatives. | |
| NO20004485L (no) | Sykloalkenderivater, deres fremstilling og anvendelse | |
| DK0976748T3 (da) | Pyrrolidinderivater med phospholispase A2-hæmmende aktivitet | |
| EP1018514A4 (en) | NF- $ g (k) B INHIBITORS CONTAINING INDANE DERIVATIVES AS ACTIVE INGREDIENT | |
| TR200403436T2 (tr) | Kristalin 1-metilkarbapenem türevleri. | |
| AU2003250471A8 (en) | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors | |
| WO2003049690A3 (en) | Hiv integrase inhibitors | |
| ATE277011T1 (de) | Flouride von 4-substituierten piperidin-derivaten | |
| ATE268751T1 (de) | Biphenylamidin-derivate | |
| DE60104697D1 (de) | Sulfonamid-derivate | |
| DK1847534T3 (da) | Thiadiazolin-derivater til behandling af kræft | |
| DE69623497D1 (de) | 1-methylcarbapenem-derivate | |
| HUP0302255A2 (hu) | Szulfonamidszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk |